Master Trading with Expert Education at Tredu

Tredu Team | Insights

Inspire Medical Systems, Inc. (NYSE: INSP) Faces Class Action Lawsuit Amid Operational Challenges

Inspire Medical Systems, Inc. (NYSE:INSP) is involved in a class action lawsuit due to alleged misleading information about its Inspire V Device launch. The company's operational failures have led to a drastic reduction in its 2025 earnings guidance by over 80%, causing a significant drop in stock price. Despite these issues, Wolfe Research upgraded Inspire's stock to "Outperform," indicating a potential recovery, with the stock currently trading at $125.22. Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company specializing in innovative solutions for sleep apnea. The company is currently embroiled in a class action lawsuit filed by Robbins LLP. The lawsuit claims that Inspire misled investors about the launch of its Inspire V Device, which was expected to significantly boost revenue. The lawsuit points out several operational failures, such as inadequate training for treatment centers and issues with IT systems. These oversights led to a drastic reduction in the company's 2025 earnings guidance by over 80%, as highlighted by the company's announcement on August 4, 2025. This news caused the stock price to drop by more than 32%, from $129.95 to $87.91, wiping out $1.2 billion in market capitalization. Despite these challenges, Wolfe Research upgraded Inspire's stock to "Outperform" on November 25, 2025, when the stock was priced at $117.29. This upgrade suggests confidence in the company's potential recovery. Currently, the stock is trading at $125.22, although it has seen a decrease of 1.66% today, equivalent to a $2.11 drop. Inspire's stock has experienced significant volatility, with a 52-week high of $216.01 and a low of $70.77. The company's market capitalization is approximately $3.71 billion, with a trading volume of 508,655 shares. Shareholders interested in joining the class action must submit their papers by January 5, 2026, with Robbins LLP handling the case on a contingency fee basis.